U.K. researchers are senselessly competing with each other for funds, GlaxoSmithKline ($GSK) CEO Andrew Witty said, and the time has come for the government to pony up £1 billion ($1.6 billion) and dedicate it to collaborative R&D across the country's academic institutions. The CEO, who also serves as chancellor of Nottingham University, said Britain needs to move beyond its provincial funding model and focus on research areas where the country's scientists have a chance for commercial breakthroughs. Article